key: cord-0892201-fjf7x3hs
authors: Shrotri, Madhumita; Navaratnam, Annalan M D; Nguyen, Vincent; Byrne, Thomas; Geismar, Cyril; Fragaszy, Ellen; Beale, Sarah; Fong, Wing Lam Erica; Patel, Parth; Kovar, Jana; Hayward, Andrew C; Aldridge, Robert W
title: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
date: 2021-07-17
journal: Lancet
DOI: 10.1016/s0140-6736(21)01642-1
sha: 63ea9718dd75bf765ee88f005bc57d5370e012fd
doc_id: 892201
cord_uid: fjf7x3hs

nan

Vaccines based on the spike glycoprotein of SARS-CoV-2 are being rolled out globally to control transmission and limit morbidity and mortality due to COVID-19. Current evidence indicates strong immunogenicity and high shortterm efficacy for BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca). 1-3 Both vaccines are delivered through a primeboost strategy, and many countries, including the UK, have used dose intervals longer than 3-4 weeks, expecting to maximise first-dose coverage and immunogenicity. With continued high global incidence, and potential for more transmissible SARS-CoV-2 variants, data on longerterm vaccine efficacy and antibody dynamics in infection-naive individuals are essential for clarifying the need for further booster doses.

To identify early indications of waning antibody levels to the spike protein (S-antibody) after complete two-dose vaccination, we did a crosssectional analysis of fully vaccinated adults (aged ≥18 years) who submitted capillary blood samples for Virus Watch, a longitudinal community cohort study in England and Wales. 4 The study received ethical approval from the Hampstead NHS Health Research Authority Ethics Committee (20/HRA/2320). Sera were tested using Elecsys Anti-SARS-CoV-2 S and N electro-chemiluminescent immunoassays (Roche Diagnostics, Basel, Switzerland); the S assay targets total antibodies to the S1 subunit of the spike protein (range 0·4-25 000 units per mL [U/mL]), whereas the N assay targets total antibodies to the fulllength nucleocapsid protein, which we took as a proxy for previous SARS-CoV-2 infection (specificity 99·8% [99·3-100]). 5 We examined the distribution of S-antibody levels for confirmed N-seronegative samples 14-20 days, 21-41 days, 42-55 days, 56-69 days, and 70 days or more after second vaccination to infer the general trend in antibody levels with time, stratified by vaccine type, with p values derived from non-parametric tests for trend. We excluded two individuals with shorter dose intervals of 21-28 days (and assumed those missing first dose date had a longer dose interval) as this has been demonstrated (in part, through preliminary data) to be less immunogenic than longer intervals for both ChAdOx1 and BNT162b2, 6,7 giving a total of 552 individuals included in the analysis.

A significant trend of declining S-antibody levels was seen with time for both ChAdOx1 (p<0·001) and BNT162b2 (p<0·001; figure; appendix), with levels reducing by about five-fold for ChAdOx1, and by about two-fold for BNT162b2, between 21-41 days and 70 days or more after the second dose. This trend remained consistent when results were stratified by sex, age, and clinical vulnerability (appendix). For BNT162b2, S-antibody levels reduced from a median of 7506 U/mL (IQR 4925-11 950) at 21-41 days, to 3320 U/mL (1566-4433) at 70 or more days. For ChAdOx1, S-antibody levels reduced from a median of 1201 U/mL (IQR 609-1865) at 0-20 days to 190 U/mL (67-644) at 70 or more days.

Across both vaccine types, women had higher initial S-antibody levels than men at 21-42 days after complete and with longitudinal follow-up of antibody dynamics in individuals over 6-12 months to establish plateau levels, or time to seroreversion. Higher antibody levels are possibly associated with greater protection against variants that can partially evade immunity, which could explain the observed higher efficacy (partly preliminary) of BNT162b2 compared to ChAdOx1 against the Delta variant (B.1.617.2). 10,11 Disparity in peak antibody levels between vaccine types, and to a lesser extent between population groups, might therefore be important if antibody levels in some groups drop below (as yet undefined) thresholds of protection earlier than in others. There is, however, accumulating evidence suggesting the importance of T-cell-mediated immunity, particularly in individuals with weak or absent antibody responses, 12 so it is possible that T-cell responses compensate to some extent as antibody responses wane.

In the context of recent advice in support of booster vaccinations from the UK's Joint Committee on Vaccination and Immunisation, 13 and given the potentially rapid S-antibody decline suggested by these data, heterologous regimens, which preliminary data suggest elicit stronger antibody and T-cell responses, 14 vaccination; also ending with higher levels at 70 days or more (appendix). Similarly, those aged 18-64 years had higher levels at 21-42 days compared to those aged 65 years and older, with correspondingly higher levels at 70 or more days (appendix).

For BNT162b2 vaccinees, some disparity was noted by clinical vulnerability status in peak antibody levels at 21-41 days, although this pattern was not observed with ChAdOx1 (appendix). At 70 days or more, the pattern of disparities was different, with higher antibody levels in vulnerable groups for BNT162b2 and the reverse for ChAdOx1. These data suggest substantial underlying heterogeneity within clinical vulnerability groupings and are also limited by small numbers in the clinically extremely vulnerable strata. However, the trend for declining S-antibody levels with time remains consistent, and the low levels in clinically vulnerable ChAdOx1 vaccinees at 70 days or more might be cause for concern.

Our data suggest waning of S-antibody levels in infection-naive individuals over a 3-10-week period after a second dose of either ChAdOx1 or BNT162b2. These data are consistent with the decline in Spike-antibody and neutralising antibody levels observed after infection, although memory B-cell populations appear to be maintained. 8, 9 As such, the clinical implications of waning antibody levels postvaccination are not yet clear, and it remains crucial to establish S-antibody thresholds associated with protection against clinical outcomes.

Although trends were consistent after stratification by key variables that are likely to affect the immune response, there might be residual confounding due to age and dosing interval as small numbers precluded more precise strata. These findings are also limited by the cross-sectional nature of the data. This analysis should be repeated with a larger number of participants to allow better adjustment for potential confounding,

Evolution of immune responses to SARS-CoV-2 in mildmoderate COVID-19

Evolution of antibody immunity to SARS-CoV-2

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv 2021

on behalf of Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers

JCVI interim advice on a potential coronavirus (COVID-19) booster vaccine programme for winter 2021 to 2022

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19 / BNT162b2 vaccination